	US 11,725,034 B2
	IL2 agonists and methods of use thereof
Jiaxi Wu, Elmsford, NY (US); Tong Zhang, Fort Lee, NJ (US); Maria del Pilar Molina-Portela, Bronx, NY (US); Eric Smith, New York, NY (US); Chia-Yang Lin, Scarsdale, NY (US); and Thomas Craig Meagher, Yorktown Heights, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Mar. 31, 2022, as Appl. No. 17/709,706.
Application 17/709,706 is a continuation of application No. 17/127,359, filed on Dec. 18, 2020.
Claims priority of provisional application 62/951,831, filed on Dec. 20, 2019.
Prior Publication US 2022/0220182 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/55 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); A61K 38/20 (2006.01); A61K 38/00 (2006.01); A61K 35/17 (2015.01); C07K 14/74 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01)

CPC C07K 14/55 (2013.01) [A61K 35/17 (2013.01); A61K 38/2013 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70539 (2013.01); C07K 14/7155 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

30 Claims

1. An IL2 agonist comprising a first polypeptide chain which comprises, in an N- to C-terminal orientation:

(a) an IgG Fc domain comprising a hinge region, wherein the hinge region comprises a first sequence derived from a first type of IgG and a second sequence derived from a second, different type of IgG; and

(b) an IL2 moiety comprising:

(i) an IL2-Ra domain comprising an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:4;

(ii) a peptide linker from 5 to 60 amino acids in length; and

(iii) an IL2 domain C-terminal to the IL2-Ra domain, wherein the IL2 domain comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:2.

13. A nucleic acid or plurality of nucleic acids encoding the IL2 agonist of claim 1.

16. A method of treating skin, breast, lung or colon cancer, comprising administering to a subject in need thereof the IL2 agonist of claim 12.